study investigating the relationship between overweight/ obesity and lifespan showed that the life expectancy of severely obese people may be reduced by an average of 10 years 6 . According to the WHO, people with a BMI from 25 to less than 30 kg/m 2 are defined as overweight , and people with a BMI ≥ 30 kg/m 2 are defined as obese 7 . Because overweight and obese people are increasing rapidly worldwide, development of medications and functional foods for prevention of obesity is required.
INTRODUCTION
Obesity is a state in which the body weight is higher than normal due to excessive fat accumulation. Development of obesity, especially accumulation of visceral fat, causes metabolic syndrome and is a risk factor for various conditions, such as impaired glucose tolerance insulin resistance , dyslipidemia, hypertension, hyperuricemia, gout, and arteriosclerosis 1 4 . Clinical studies have revealed that maintaining an appropriate body mass index BMI is extremely important for healthy longevity 5 . In fact, a large-scale vegetables and fruits. They are classified as carotenes, which are hydrocarbons, and xanthophylls that contain oxygen atoms in addition to carbon/hydrogen atoms. Both xanthophylls and carotenes are known to have strong antioxidant activity, but the activity is higher in xanthophylls 8 , and its various effects on human physiology have also been reported. For example, β-cryptoxanthin has been suggested to reduce the risk of obesity, diabetes, and arteriosclerosis 9 11 . It was also reported that astaxanthin improved the brain function of healthy volunteers who were aware of forgetfulness 12, 13 . Furthermore, it is known that lutein and zeaxanthin accumulate in the eyes and are effective for prevention of age-related macular degeneration 14 16 . Thus, various xanthophylls have potential as functional food ingredients that can contribute to human health. Ripe red paprika differs from other carotenoid-rich vegetables e.g.; carrots, tomatoes, and spinach with respect to the abundance and composition of xanthophylls 17 20 . It has been reported that characteristic paprika xanthophylls like capsanthin, capsorubin, and cryptocapsin have strong antioxidant, anti-inflammatory, and anti-tumor effects 21 28 . Since paprika also contains an abundance of other xanthophylls, including β-cryptoxanthin, zeaxanthin, and cucurbitaxanthin A, it is a healthy functional food. We established a method of producing a paprika xanthophyll preparation containing at least seven different xanthophylls capsanthin, capsorubin, cucurbitaxanthin A, β-cryptoxanthin, zeaxanthin, cryptocapsin and capsanthin 3,6-epoxide together with a relatively small amount of β-carotene, and we have been investigating the properties, distribution, and function of these xanthophylls 21 24 . In the present study, we investigated whether oral administration of paprika xanthophylls could improve parameters related to obesity in overweight adult volunteers BMI ≥ 25 kg/m 2 to 30 kg/ m 2 . In brief, 100 subjects were randomly divided into two groups, and changes of the abdominal fat area visceral fat area, subcutaneous fat area, and total fat area , BMI, and laboratory parameters were compared between the group taking capsules containing paprika xanthophylls and the group taking placebo capsules. After 12 weeks, a significant decrease of the abdominal fat area and BMI was observed in the paprika xanthophyll group compared with the placebo group. To our knowledge, this is the first evidence that intake of paprika xanthophylls can reduce fat stores in humans. Our findings suggest that paprika xanthophylls may be an effective food ingredient for suppressing obesity.
Materials and Methods

Study procedures
The study protocol and informed consent document conformed to the Declaration of Helsinki, and were approved by the ethics committee of AMC Nishi-umeda Clinic Osaka, Japan . All of the subjects provided written informed consent prior to participation. This study was regi s t e r e d w i t h t h e U M I N C l i n i c a l Tr i a l s R e g i s t r y UMIN000021529; Title: Verification of the antiobesity effect of a plant extract ingredient G-PX . The study was conducted in compliance with the protocol and was performed by a contract research organization A2 Healthcare Corporation, Tokyo, Japan from February to September 2016 at the AMC Nishi-umeda Clinic Osaka, Japan and the Nakanoshima Clinic Osaka, Japan .
Subjects
Healthy Japanese volunteers were recruited if they were aged 20 years and had a BMI from 25 to 30 kg/m 2 , which is classified as overweight by the WHO. The candidate subjects were not using medications that could potentially influence the results. Exclusion criteria were as follows: 1 serious diseases e.g., hepatic, renal, or cardiovascular disease, asthma, cancer, or diabetes ; 2 a past history of gastrectomy or intestinal resection that could affect digestion or absorption; 3 current use of prescription medication; 4 pregnancy or breastfeeding; 5 severe food allergy; 6 use of supplements astaxanthin, β-carotene, and lutein that could influence the results; 7 current participation in another clinical study; 8 donation of 200 mL of blood or blood components within 4 weeks prior to enrollment in this study; 9 donation of 400 mL of blood within 16 weeks prior to enrollment in this study; 10 donation of 1000 mL of blood within 64 weeks prior to enrollment in this study; and 11 any other reason for which a subject was judged to be ineligible by the principal investigator or the study site investigators.
Paprika xanthophyll preparation and quantitative
analysis of plasma carotenoids A commercial paprika xanthophyll preparation PapriX ; Glico Nutrition Co., Ltd, Osaka, Japan was employed for this study. Its xanthophyll composition is shown in Table 1 . This preparation contained mainly seven xant h o p h y l l s c a p s a n t h i n , c u c u r b i t a x a n t h i n A , βcryptoxanthin, zeaxanthin, capsorubin, cryptocapsin, and capsanthin 3,6-epoxide and one carotene β-carotene 21 . Gelatin capsules containing PapriX-oil total xanthophyll content of 9.0 mg per capsule were used as the test substance. Gelatin capsules containing vegetable oil and caramel coloring that were indistinguishable from the test substance were used as the placebo. The subjects took one capsule daily after the evening meal for 12 weeks.
Plasma levels of several carotenoids were determined as described previously 21 . After the blood sample was let stand at room temperature for 30 min, plasma was obtained by centrifugation 5,000 rpm for 10 min at room temperature and was stored at 80 until analysis of carotenoids. After thawing, 2 mL of ethanol was added to 1 mL of plasma and stirred, followed by extraction of carotenoids by using 5 mL of ether : hexane 2 : 8, v/v solution with stirring. After being let stand for 10 min, the upper layer was filtered through a Millipore membrane filter Millipore Corporation, Massachusetts, USA and was evaporated to dryness. Then the residue was dissolved in acetone : hexane 2 : 8, v/v and was subjected to high performance liquid chromatography HPLC for analysis of plasma carotenoids by our routine method 29 . In brief, HPLC was performed with a Hitachi L-6000 intelligent pump, an L-4250 UV-VIS detector set at 450 nm, and a 5 mm Cosmosil 5SL-II 250 4.6 mm i.d. column Nacalai Tesque, Kyoto, Japan . The mobile phase was acetone : hexane 2 : 8, v/v at a flow rate of 1.0 mL/min. Identification of each carotenoid was performed by comparing its retention time with those of authentic paprika carotenoids and the content of each carotenoid was calculated from the peak areas.
Study design
This was a randomized, double-blind, placebo-controlled intervention study that was conducted according to the Consolidated Standards of Reporting Trials CONSORT statement. This study consisted of an 8-week screening period, followed by a 12-week treatment period. During the screening period, subjects were screened for eligibility by performing an interview with an investigator and undergoing measurement of anthropometric parameters height, weight, BMI, and body fat ratio , measurement of physical parameters blood pressure and pulse rate , and blood and urine tests. The 100 eligible subjects were randomly divided into two groups the paprika xanthophyll group and the placebo group by the grouping controller. The controller randomized the subjects to each group at a 1:1 ratio using a table of random numbers, and stored the assignment list in a sealed container until completion of all analyses. Apart from the controller, all of the investigators and data processors, as well as all of the subjects, were blinded to the treatment assigned until the end of this trial.
During the treatment period, each subject took 1 paprika xanthophyll capsule or 1 placebo capsule after the evening meal every day. Subjects were instructed to continue their usual pattern of diet, exercise, sleeping, smoking, and drinking. They were also instructed to avoid blood donation, commencing a new exercise regimen, and use of dietary supplements that could potentially influence the results of the study until after the end of the study period. In week 0 before starting administration and week 12 of the treatment period, subjects underwent computed tomography CT , interview by a site investigator, measurement of anthropometric, physical, blood, and urine parameters, and the confirmation of the dairy record. On the day before each set of tests, subjects were prohibited from drinking alcohol and performing excessive exercise, and had to finish the evening meal by 22:00. After that, only intake of water was allowed until the tests were completed on the following day.
Anthropometric measurements and body composition
While the subject was standing, height and weight were measured to the nearest 0.1 cm and 0.1 kg, respectively. The body fat ratio and visceral fat level were measured by bioelectrical impedance analysis using a body composition monitor innarScan Dual RD-501; Tanita Co., Tokyo, Japan . The BMI was calculated as body weight kg divided by the square of height m . Blood pressure and pulse rate were measured once with the subject in the sitting position after resting.
Measurement of the abdominal fat area
The abdominal visceral fat area VFA and the abdominal subcutaneous fat area SFA were measured on CT scans acquired with an Aquilion 64 scanner TSX-101A, Toshiba Medical Systems Co., Ltd. at Nakanoshima Clinic Osaka, Japan . With the subject in the supine position, four CT scans 120 kV, 6 mm slice thickness were acquired at the level of the L4-5 vertebrae. Then VFA, SFA, and total fat area TFA VFA SFA were calculated from the CT data.
Biochemical parameters
Fasting blood samples were collected for determination 3.5 0 *Active or placebo capsules were ingested once daily 1 capsule/day . Table 1 Xanthophyll contents of the active and placebo capsules.
of hematology parameter white blood cell count WBC , red blood cell count RBC , hemoglobin Hb , hematocrit Ht , and platelet count Plt and blood chemistry parameters aspartate aminotransferase AST , alanine aminotransferase ALT , γ-glutamyl transpeptidase γ-GTP , alkaline phosphatase ALP lactate dehydrogenase LDH , total bilirubin T-Bil , creatinine Cre , blood urea nitrogen BUN , total cholesterol T-cho , high-density lipoprotein cholesterol HDL-cho , low-density lipoprotein cholesterol LDL-cho , triglycerides TG , glucose Glc , uric acid UA , albumin Alb , creatine phosphokinase CPK , total protein TP , sodium Na , potassium K , chloride Cl , calcium Ca , hemoglobin A1c HbA1c , adiponectin Adn , leptin Lpt , and glycoalbumin GA . In addition, fasting urine samples were obtained to measure urinary protein, glucose, and urobilinogen. All samples were analyzed by LSI Medience Corporation.
Endpoints
The primary endpoint was the change of abdominal VFA after the 12-week treatment period. The secondary endpoints were as follows: 1 changes of abdominal SFA and TFA; 2 change of BMI; and 3 changes of lipid-related parameters T-cho, HDL-cho, LDL-cho, TG, Adn, and Lpt , glucose metabolism-related parameters Glc, HbA1c, GA , and other blood parameters AST, ALT, γ-GTP, and UA . 
Statistical analysis
Results were expressed as actual values or as the changes from week 0. The paired t-test was used to evaluate the significance of changes from before treatment in each group, while the unpaired t-test was used to compare differences between the paprika xanthophyll group and the placebo group. In addition, Bowker s test and the Wilcoxon rank sum test were used for analysis of data on the body fat ratio and on urine protein, glucose, and urobilinogen. A difference of p 0.05 was considered significant. All statistical analyses were performed using SAS software release 9.2, SAS Institute Japan Co., Ltd. or Microsoft Excel 2010.
RESULTS
Disposition of the subjects
We provisionally recruited 171 subjects from March to April 2016, but 71 subjects were ineligible according to the inclusion and exclusion criteria. The remaining 100 participants were judged to be eligible by the site investigators and were randomized to the paprika xanthophyll group and the placebo group 50 subjects per group . Figure 1 shows a flow diagram of this study. Two subjects dropped out for personal reasons unrelated to ingestion of the study capsules. Among the 98 remaining subjects who finished the study 48 in the paprika xanthophyll group and 50 in the placebo group , 18 subjects 7 and 11, respectively were excluded from analysis before unblinding due to significant lifestyle changes, initiation of new exercise, or serious compliance violations. In addition, 5 subjects 4 and 1, re-spectively were excluded from analysis of the CT data abdominal VFA, SFA, TFA, and abdominal circumference because the site investigators judged their CT scans to be of insufficient quality. Thus, there were 41 subjects for analysis in the paprika xanthophyll group and 39 subjects in the placebo group, with analysis of CT data being done in 37 and 38 subjects, respectively. There were no significant differences of baseline data between the paprika xanthophyll and placebo groups Table 2 . The test capsule ingestion rate was 99.8 in the paprika xanthophyll group and 99.5 in the placebo group. Table 3 shows the VFA, SFA, TFA, and waist circumference determined by CT scanning at weeks 0 and 12, as well as the changes from week 0 baseline . The decrease of VFA from week 0 to week 12 was 2.82 2.19 cm 2 in the paprika xanthophyll group and 0.43 2.47 cm 2 in the placebo group. Although the change of VFA after 12 weeks was larger in the paprika xanthophyll group than in the placebo group, there was no significant difference between the two groups.
Effect of paprika xanthophyll supplementation on the abdominal fat area
As shown in Table 3 , SFA and TFA both decreased significantly by week 12 compared with week 0 in the paprika xanthophyll group, but SFA and TFA increased in the placebo group. When compared with the placebo group, SFA and TFA showed a significant decrease in the paprika xanthophyll group by week 12. In addition, we analyzed the waist circumference on abdominal CT scans. Waist circumference decreased significantly from week 0 to week 
Total
Data are expressed as the mean SEM. BMI: body mass index, SBP: systolic blood pressure. DBP: diastolic blood pressure. Active or placebo capsules were ingested once daily 1 capsule/day . 12 in the paprika xanthophyll group and the change of waist circumference from week 0 was significantly larger than in the placebo group. Additionally, the waist circum-ference was significantly smaller in the paprika xanthophyll group than in the placebo group by week 12. These results suggested that daily intake of paprika xanthophylls de- Table 4 shows the values measured in weeks 0 and 12, as well as the changes from week 0, for body weight, BMI, body fat ratio, and visceral fat level. In the paprika xanthophyll group, BMI and body weight were significantly reduced by week 12 compared with week 0, while no significant change were observed in the placebo group. Moreover, BMI and the body weight were significantly lower in the paprika xanthophyll group than in the placebo group, and the changes of BMI and body weight were significantly larger in the active treatment group. The body fat ratio showed significant reduction from week 0 in both groups, but there was no significant difference between them. Visceral fat level did not decrease significantly in either group, although the change from week 0 was larger in the paprika xanthophyll group than in the placebo group. These find-ings indicated that paprika xanthophyll intake can improve several body indices, such as BMI and body weight, in health overweight subjects.
Effect of paprika xanthophyll supplementation on anthropomorphic indices
Effect of paprika xanthophyll supplementation on laboratory parameters
Parameters of lipid and glucose metabolism determined in weeks 0 and 12 are displayed in Table 5 . In the paprika xanthophyll group, T-Cho and LDL-Cho decreased significantly after 12 weeks, but no significant changes were observed in the placebo group. The LDL/HDL ratio an index of the risk of arteriosclerotic disease was significantly improved by intake of paprika xanthophylls, but not by Data are expressed as the mean SEM. Paprika xanthophyll active group n 41 , placebo group n 39 , TP: total protein, Alb: albumin, T-Bil: total bilirubin, AST: aspartate aminotransferase, ALT: alanine aminotransferase, g-GTP: g-glutamyl transpeptidase, LDH: lactate dehydrogenase, ALP: alkaline phosphatase. Differences between the active and placebo groups were determined with the unpaired t-test. Comparisons between week 12 and week 0 baseline were done with the paired t-test. *: p 0.05, **: p 0.01 vs. week 0. Table 6 Effect of paprika xanthophyll intake on liver function.
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placebo intake. Although adiponectin, HbA1c, and GA showed significant differences from week 0 in one or both groups, the actual changes were very small and within the respective reference ranges. In both groups, there were no significant changes of HDL-Cho, TG, leptin, and Glc. Taken together, these results suggested that intake of paprika xanthophylls could improve parameters of lipid metabolism T-Cho, LDL-Cho, and the LDL/HDL ratio in healthy sub-jects. Tables 6 and 7 show the effects of paprika xanthophyll intake on parameters of liver function, kidney function, and electrolytes. Although TP, Alb, LDH, UA female subjects , Cre female subjects , and Ca showed significant changes from week 0 to week 12 in one or both groups, these changes were small and within the respective reference ranges. There were no significant variations of T-Bil, AST, Data are expressed as the mean SEM. Paprika xanthophyll active group n 41 , placebo group n 39 , UA: uric acid, BUN: blood urea nitrogen, Cre: creatinine, CPK: creatine phosphorus kinase, Na: sodium, Cl: chloride, K: potassium, Ca: calcium. Differences between the active and placebo groups were determined with the unpaired t-test. Comparisons between week 12 and week 0 baseline were done with the paired t-test. *: p 0.05 vs. week 0. Table 7 Effect of paprika xanthophyll intake on renal function and electrolytes.
ALT, γ-GTP, ALP, UA male subjects , BUN, Cre male subjects , CPK, Na, Cl, and K in both groups.
Tables 8 and 9 summarize the effects of paprika xanthophyll intake on hematology and circulatory parameters. Although RBC and Hb showed significant changes after 12 weeks in male subjects from the paprika xanthophyll group, the changes were very small and within the respective reference ranges. After 12 weeks, the DBP was not significantly lower in either group, but the change of DBP was significantly smaller in the paprika xanthophyll group than in the placebo group. On the other hand, WBC, RBC female subjects , Hb female subjects , Ht, Plt, SBP, and pulse rate showed no significant variations in both groups. Figure 2 shows serum xanthophyll levels in weeks 0 and 12. After intake of the paprika xanthophyll capsule, the serum levels of capsanthin, capsanthon, zeaxanthin, β-cryptoxanthin, and cucurbitaxanthin A were significantly elevated in week 12 compared with week 0, while the serum level of lutein not contained in the capsules was unchanged Fig. 2 . On the other hand, the serum levels of zeaxanthin, β-cryptoxanthin, and lutein showed an increase after ingestion of placebo capsules. In addition, the serum l e v e l s o f c a p s a n t h i n , c a p s a n t h o n , z e a x a n t h i n , β-cryptoxanthin, and cucurbitaxanthin A supplementation were significantly higher in the paprika xanthophyll group than in the placebo group after 12 weeks.
During the study period, the only adverse event reported was elevation of CRP in 1 subject from the paprika xanthophyll group. According to the investigator, there was no relation between this event and intake of paprika xanthophyll capsules.
DISCUSSION
This randomized, double-blind, placebo-controlled study investigated whether oral paprika xanthophyll supplementation reduced abdominal fat in healthy overweight sub-Placebo Active 5862±229
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Data are expressed as the mean SEM. Paprika xanthophyll active group n 41 , placebo group n 39 , WBC: white blood cell count, RBC: red blood cell count, Hb: hemoglobin, Ht: hematocrit, Plt: platelet count. Differences between the active and placebo groups were determined with the unpaired t-test. Comparisons between week 12 and week 0 baseline were done with the paired t-test. *: p 0.05, **: p 0.01 vs. week 0. Table 8 Effect of paprika xanthophyll intake on hematological parameters.
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jects with a BMI from 25 to 30 kg/m 2 , revealing that the abdominal fat area SFA and TFA assessed by CT decreased significantly after 12 weeks in the paprika xanthophyll group compared with the placebo group. In addition, the BMI, body weight, abdominal circumference, and DBP were significantly lower in the paprika xanthophyll group than in the placebo group after 12 weeks. Furthermore, lipid metabolism parameters including body fat ratio, T-Cho, LDL-Cho, and LDL/HDL ratio showed significant improvement compared with week 0 in the paprika xanthophyll group. These findings suggest that oral paprika xanthophyll supplementation decreases the accumulation of abdominal fat and improves parameters of lipid metabolism in healthy overweight subjects. No adverse events related to intake of paprika xanthophyll capsules were detected during the study period, suggesting that paprika xanthophylls can be used safely as a food ingredient to improve metabolic syndrome.
The active capsules used in this study contained mainly seven xanthophylls capsanthin, cucurbitaxanthin A, βcryptoxanthin, zeaxanthin, capsorubin, cryptocapsin, and capsanthin 3,6-epoxide and one carotene β-carotene 21 . These carotenoids have very strong antioxidant activity and act as scaventgers of reactive oxygen species ROS . The singlet oxygen quenching activity of capsorubin, capsanthin, and cucurbitaxanthin A is more than 25 times stronger than that of β-carotene, and these xanthophylls also show greater antioxidant activity than astaxanthin, which was reported to be a strong antioxidant in vitro study 21 . Furthermore, capsorbin, capsanthin, and zeaxanthin can quench hydroxyl radicals, which are one type of ROS 22 . It was previously reported that orally administered paprika xanthophylls were absorbed by the small intestine in humans, and were subsequently found in the plasma and red blood cell membranes 21 . Accordingly, paprika xanthophylls administered orally may efficiently scavenge ROS at various sites in the body, suggesting that such xanthophylls could be utilized as an antioxidant element in foods and medications. On the other hand, there is no report that antioxidant activity such as singlet oxygen scavenging ability improves lipid metabolism and decreases abdominal fat. For this reason, we speculate that the effect of paprika xanthophyll supplementation on abdominal fat degradation is involved in a mechanism different from antioxidant effect.
It has recently been reported that particular xanthophylls and carotenes possess various functions in addition to antioxidant activity. For example, it is known that supplementation of lutein and/or zeaxanthin can have a protective effect against age-related macular degeneration, which is a major cause of visual impairment in the elderly 30 . In addition, Shirasawa et al. reported that oral intake of astaxanthin derived from Haematococcus pluvialis improved cognitive function working memory and response time in healthy volunteers with age-related forgetf u l n e s s 12, 13 . T h e r e h a v e a l s o b e e n r e p o r t s t h a t β-cryptoxanthin supplementation may improve conditions such as osteoporosis, hepatic dysfunction, dyslipidemia, and arteriosclerosis 31 37 . Sugiura et al. found that the serum level of β-cryptoxanthin was closely correlated with the risk of several lifestyle-related diseases 9 11, 31 33 , while Suzuki et al. reported that a higher serum β-cryptoxanthin level was associated with a significantly lower odds ratio for metabolic syndrome 34 Data are expressed as the mean SEM. Paprika xanthophyll active group n 41 , placebo group n 39 , SBP: systolic blood pressure, DBP: diastolic blood pressure. Differences between the active and placebo groups were determined with the unpaired t-test. Comparisons between week 12 and week 0 baseline were done with the paired t-test. #: p 0.05 vs. placebo group. Table 9 Effect of paprika xanthophyll intake on circulatory parameters. Fig. 2 Serum levels of xanthophylls in week 0 and week 12. Data are expressed as the mean SD. Paprika xanthophyll active group n = 41 , placebo group n = 39 . White and black bar in the graph indicate placebo group and active group, respectively. Differences between the active and placebo groups were determined with the unpaired t-test. Comparisons between week 0 and week 12 were performed by using the paired t-test. ##: p 0.01, ###: p 0.001 vs. placebo group. *: p 0.05, **: p 0.01, ***: p 0.001 vs. week 0. 0.5 mg/day for 12 weeks in patients with mild/moderate obesity 35 . It has been suggested that peroxisome proliferator-activated receptor PPAR -α and PPAR-γ expressed by adipocytes might be involved in the mechanism of fat reduction by β-cryptoxanthin 36, 37 . These reports strongly suggest that β-cryptoxanthin has a role in reducing abdominal fat in obese subjects. In the present study, β-cryptoxanthin was one of components of the paprika xanthophyll preparation and subjects in the paprika xanthophyll group ingested 0.5 mg of β-cryptoxanthin every day. Accordingly, β-cryptoxanthin may have played an important role in reducing the abdominal fat area in the paprika xanthophyll group. In addition, Maeda et al. reported that other xanthophylls contained in paprika xanthophyll might contribute to improve lipid metabolism 28 . They showed that oral intake of paprika xanthophylls improved serum levels of LDL-Cho and adiponectin in high fat fed mice, and that capsanthin and capsorubin included in paprika xanthophyll activated PPAR-γ to improve lipid metabolism by converting hypertrophy adipocyte to compact adipocyte. These reports suggest that not only β-cryptoxanthin but also other xanthophylls in paprika xanthophyll relate to enhance the differentiation to compact adipocyte. Therefore, several of the xanthophylls in the paprika xanthophyll preparation that we tested in this study may have acted together to reduce the abdominal fat area.
CONCLUSIONS
In summary, we performed a randomized, double-blind, placebo-controlled human trial to investigate the effect of oral paprika xanthophyll supplementation on fat reduction in healthy overweight subjects. Our findings demonstrated that paprika xanthophyll supplementation reduced the abdominal fat area. In addition, it was suggested that administration of paprika xanthophyll improves the lipid metabolic parameters of these volunteers. To the best of our knowledge, this is the first randomized controlled trial to show a fat-reducing effect of paprika xanthophyll intake in humans. Since xanthophylls have been reported to have various other actions besides fat reduction, we are currently examining such effects of paprika xanthophylls improvement of cognitive function, antioxidant effect, and anti-inflammatory effect in clinical randomized trials.
